Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL-mediated NF-κB and JNK and their downstream signalling pathways

Targeting excessive osteoclast differentiation and activity is considered a valid therapeutic approach for osteoporosis. Zoledronic acid (ZOL) plays a pivotal role in regulating bone mineral density. However, the exact molecular mechanisms responsible for the inhibitory effects of ZOL on receptor ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiao-Lin, Liu, Chao, Shi, Xue-Mei, Cheng, Yu-Ting, Zhou, Qian, Li, Jian-Ping, Liao, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711024/
https://www.ncbi.nlm.nih.gov/pubmed/34935053
http://dx.doi.org/10.3892/mmr.2021.12575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711024/
https://www.ncbi.nlm.nih.gov/pubmed/34935053
http://dx.doi.org/10.3892/mmr.2021.12575

Ejemplares similares